share_log

4: Statement of changes in beneficial ownership of securities-Officer Byrnes Michael

4: Statement of changes in beneficial ownership of securities-Officer Byrnes Michael

4:持股变动声明-高管 Byrnes Michael
美股SEC公告 ·  05/17 16:03

Moomoo AI 已提取核心信息

Michael Byrnes, the Chief Financial Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,387 shares of common stock on May 15, 2024. The transaction was carried out at a price of $1.683 per share, resulting in a total investment of approximately $2,335. The acquisition was made directly and is part of a grant, award, or other acquisition. Following this transaction, Byrnes holds a total of 3,117 shares in the company. The transaction reflects the CFO's growing stake in eFFECTOR Therapeutics and could be a signal of confidence in the company's future prospects.
Michael Byrnes, the Chief Financial Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,387 shares of common stock on May 15, 2024. The transaction was carried out at a price of $1.683 per share, resulting in a total investment of approximately $2,335. The acquisition was made directly and is part of a grant, award, or other acquisition. Following this transaction, Byrnes holds a total of 3,117 shares in the company. The transaction reflects the CFO's growing stake in eFFECTOR Therapeutics and could be a signal of confidence in the company's future prospects.
Effector Therapeutics, Inc.(EFTR)的首席财务官迈克尔·伯恩斯于2024年5月15日完成了对1387股普通股的购买。该交易以每股1.683美元的价格进行,总投资约为2335美元。此次收购是直接进行的,是拨款、奖励或其他收购的一部分。在这笔交易之后,伯恩斯共持有该公司3,117股股份。该交易反映了首席财务官在Effector Therapeutics的股份不断增加,可能表明了对公司未来前景的信心。
Effector Therapeutics, Inc.(EFTR)的首席财务官迈克尔·伯恩斯于2024年5月15日完成了对1387股普通股的购买。该交易以每股1.683美元的价格进行,总投资约为2335美元。此次收购是直接进行的,是拨款、奖励或其他收购的一部分。在这笔交易之后,伯恩斯共持有该公司3,117股股份。该交易反映了首席财务官在Effector Therapeutics的股份不断增加,可能表明了对公司未来前景的信心。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息